Allogeneic “Zombie Cell” as Off‐The‐Shelf Vaccine for Postsurgical Cancer Immunotherapy
Abstract Allogeneic tumor cell vaccines provide off‐the‐shelf convenience but lack patient specificity due to heterogeneity in tumor antigens. Here, allogeneic tumor cell corpses are converted into “zombie cells” capable of assimilating heterogeneous tumor by seizing cancer cells and spreading adjuv...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-04-01
|
| Series: | Advanced Science |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/advs.202307030 |
| _version_ | 1797227520061341696 |
|---|---|
| author | Bo Li Ping Zhang Junlin Li Rui Zhou Minglu Zhou Chendong Liu Xi Liu Liqiang Chen Lian Li |
| author_facet | Bo Li Ping Zhang Junlin Li Rui Zhou Minglu Zhou Chendong Liu Xi Liu Liqiang Chen Lian Li |
| author_sort | Bo Li |
| collection | DOAJ |
| description | Abstract Allogeneic tumor cell vaccines provide off‐the‐shelf convenience but lack patient specificity due to heterogeneity in tumor antigens. Here, allogeneic tumor cell corpses are converted into “zombie cells” capable of assimilating heterogeneous tumor by seizing cancer cells and spreading adjuvant infection. This causes pseudo‐oncolysis of tumors, transforming them into immunogenic targets for enhanced phagocytosis. It is shown that in postoperative tumor models, localized delivery of premade “zombie cells” through stepwise gelation in resection cavity consolidates tumor surgery. Compared to analogous vaccines lacking “seizing” or “assimilating” capability, “zombie cell” platform effectively mobilizes T cell response against residual tumors, and establishes immunological memory against tumor re‐challenge, showing less susceptibility to immune evasion. Despite using allogeneic sources, “zombie cell” platform functions as generalizable framework to produce long‐term antitumor immunity in different tumor models, showing comparable effect to autologous vaccine. Together, with the potential of off‐the‐shelf availability and personalized relevance to heterogenous tumor antigens, this study suggests an alternative strategy for timely therapy after tumor surgery. |
| first_indexed | 2024-04-24T14:42:06Z |
| format | Article |
| id | doaj.art-d7739c8a245740c5844dc37d5e213e60 |
| institution | Directory Open Access Journal |
| issn | 2198-3844 |
| language | English |
| last_indexed | 2024-04-24T14:42:06Z |
| publishDate | 2024-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advanced Science |
| spelling | doaj.art-d7739c8a245740c5844dc37d5e213e602024-04-02T20:51:56ZengWileyAdvanced Science2198-38442024-04-011113n/an/a10.1002/advs.202307030Allogeneic “Zombie Cell” as Off‐The‐Shelf Vaccine for Postsurgical Cancer ImmunotherapyBo Li0Ping Zhang1Junlin Li2Rui Zhou3Minglu Zhou4Chendong Liu5Xi Liu6Liqiang Chen7Lian Li8Key Laboratory of Drug‐Targeting and Drug Delivery System of the Education Ministry and Sichuan Province Sichuan Engineering Laboratory for Plant‐Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology West China School of Pharmacy Sichuan University Chengdu 610041 ChinaKey Laboratory of Drug‐Targeting and Drug Delivery System of the Education Ministry and Sichuan Province Sichuan Engineering Laboratory for Plant‐Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology West China School of Pharmacy Sichuan University Chengdu 610041 ChinaKey Laboratory of Drug‐Targeting and Drug Delivery System of the Education Ministry and Sichuan Province Sichuan Engineering Laboratory for Plant‐Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology West China School of Pharmacy Sichuan University Chengdu 610041 ChinaNMPA Key Laboratory for Technical Research on Drug Products In Vitro and In Vivo Correlation Sichuan Institute for Drug Control Chengdu 611730 ChinaKey Laboratory of Drug‐Targeting and Drug Delivery System of the Education Ministry and Sichuan Province Sichuan Engineering Laboratory for Plant‐Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology West China School of Pharmacy Sichuan University Chengdu 610041 ChinaKey Laboratory of Drug‐Targeting and Drug Delivery System of the Education Ministry and Sichuan Province Sichuan Engineering Laboratory for Plant‐Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology West China School of Pharmacy Sichuan University Chengdu 610041 ChinaKey Laboratory of Drug‐Targeting and Drug Delivery System of the Education Ministry and Sichuan Province Sichuan Engineering Laboratory for Plant‐Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology West China School of Pharmacy Sichuan University Chengdu 610041 ChinaKey Laboratory of Drug‐Targeting and Drug Delivery System of the Education Ministry and Sichuan Province Sichuan Engineering Laboratory for Plant‐Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology West China School of Pharmacy Sichuan University Chengdu 610041 ChinaKey Laboratory of Drug‐Targeting and Drug Delivery System of the Education Ministry and Sichuan Province Sichuan Engineering Laboratory for Plant‐Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology West China School of Pharmacy Sichuan University Chengdu 610041 ChinaAbstract Allogeneic tumor cell vaccines provide off‐the‐shelf convenience but lack patient specificity due to heterogeneity in tumor antigens. Here, allogeneic tumor cell corpses are converted into “zombie cells” capable of assimilating heterogeneous tumor by seizing cancer cells and spreading adjuvant infection. This causes pseudo‐oncolysis of tumors, transforming them into immunogenic targets for enhanced phagocytosis. It is shown that in postoperative tumor models, localized delivery of premade “zombie cells” through stepwise gelation in resection cavity consolidates tumor surgery. Compared to analogous vaccines lacking “seizing” or “assimilating” capability, “zombie cell” platform effectively mobilizes T cell response against residual tumors, and establishes immunological memory against tumor re‐challenge, showing less susceptibility to immune evasion. Despite using allogeneic sources, “zombie cell” platform functions as generalizable framework to produce long‐term antitumor immunity in different tumor models, showing comparable effect to autologous vaccine. Together, with the potential of off‐the‐shelf availability and personalized relevance to heterogenous tumor antigens, this study suggests an alternative strategy for timely therapy after tumor surgery.https://doi.org/10.1002/advs.202307030biomedical engineeringcell deliverylocalized therapypostsurgical immunotherapywhole tumor cell vaccine |
| spellingShingle | Bo Li Ping Zhang Junlin Li Rui Zhou Minglu Zhou Chendong Liu Xi Liu Liqiang Chen Lian Li Allogeneic “Zombie Cell” as Off‐The‐Shelf Vaccine for Postsurgical Cancer Immunotherapy Advanced Science biomedical engineering cell delivery localized therapy postsurgical immunotherapy whole tumor cell vaccine |
| title | Allogeneic “Zombie Cell” as Off‐The‐Shelf Vaccine for Postsurgical Cancer Immunotherapy |
| title_full | Allogeneic “Zombie Cell” as Off‐The‐Shelf Vaccine for Postsurgical Cancer Immunotherapy |
| title_fullStr | Allogeneic “Zombie Cell” as Off‐The‐Shelf Vaccine for Postsurgical Cancer Immunotherapy |
| title_full_unstemmed | Allogeneic “Zombie Cell” as Off‐The‐Shelf Vaccine for Postsurgical Cancer Immunotherapy |
| title_short | Allogeneic “Zombie Cell” as Off‐The‐Shelf Vaccine for Postsurgical Cancer Immunotherapy |
| title_sort | allogeneic zombie cell as off the shelf vaccine for postsurgical cancer immunotherapy |
| topic | biomedical engineering cell delivery localized therapy postsurgical immunotherapy whole tumor cell vaccine |
| url | https://doi.org/10.1002/advs.202307030 |
| work_keys_str_mv | AT boli allogeneiczombiecellasofftheshelfvaccineforpostsurgicalcancerimmunotherapy AT pingzhang allogeneiczombiecellasofftheshelfvaccineforpostsurgicalcancerimmunotherapy AT junlinli allogeneiczombiecellasofftheshelfvaccineforpostsurgicalcancerimmunotherapy AT ruizhou allogeneiczombiecellasofftheshelfvaccineforpostsurgicalcancerimmunotherapy AT mingluzhou allogeneiczombiecellasofftheshelfvaccineforpostsurgicalcancerimmunotherapy AT chendongliu allogeneiczombiecellasofftheshelfvaccineforpostsurgicalcancerimmunotherapy AT xiliu allogeneiczombiecellasofftheshelfvaccineforpostsurgicalcancerimmunotherapy AT liqiangchen allogeneiczombiecellasofftheshelfvaccineforpostsurgicalcancerimmunotherapy AT lianli allogeneiczombiecellasofftheshelfvaccineforpostsurgicalcancerimmunotherapy |